Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial Stats
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT06863233
A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer
Overview
The purpose of this study to learn whether PET/CT (positron emission tomography/computed tomography) scans using an imaging agent (radiotracer) called zirconium Zr 89 crefmirlimab berdoxam is a safe and effective way to identify CD8+ T cells
Sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1
Contacts
Alexander Shoushtari, MD (CONTACT)
shoushta@mskcc.org
646-888-4161
Adam Schoenfeld, MD (CONTACT)
schoenfa@mskcc.org
646-608-4042
Adam Schoenfeld, MD (PRINCIPAL_INVESTIGATOR)
ClinicalTrials.gov
NCT06863233Drug / Compound
crefmirlimab berdoxam
Isotope(s):
ZIRCONIUM-89
Radioisotope: Zr89
Theranostic Role: PET Imaging
T1/2 (Half-Life): 78 Hours
Decay Mode: POSITRON β+ (22%), ELECTRON CAPTURE (76%), GAMMA
Energy: max 0.9 MeV, E mean 397 keV, Gamma 511 keV
Range: N/A
Decay Daughters: Y89 (Stable)
Status: Clinical Trials Only
Target(s):
- CD8 Cells
Ligand Class: Small Proteins and Antibody Fragments
Chelator: DFO
Eligibility
Inclusion
- Patient is enrolled in the engineered TIL cell therapy protocol OBX115-23-01, but has not received the treatment yet.
- Patient has a histologically confirmed diagnosis of metastatic non-small cell lung cancer
Exclusion
- Patients with a history of splenectomy or significant splenic dysfunction (e.g., as evidenced by splenomegaly or a history of recurrent infections due to impaired immune function)
Share your feedback
Help us improve your experience